Core Viewpoint - China Biopharmaceutical (01177) has experienced double-digit revenue growth in the first half of the year, driven by the expansion of innovative drugs and biosimilars, while overall profit has seen significant growth due to investment income, although core pharmaceutical business segment profit is slightly under pressure in the short term due to increased R&D investment [1] Group 1: Financial Performance - The target price for China Biopharmaceutical has been raised from HKD 8 to HKD 9.1, maintaining a "Buy" rating [1] - The company’s revenue forecast for 2025 has been increased by 4% to reflect contributions from milestone payments related to technology transfers [1] - Adjusted net profit estimates for China Biopharmaceutical for 2025, 2026, and 2027 have been raised to RMB 5.1 billion, RMB 4.4 billion, and RMB 5.3 billion respectively, reflecting higher investment income forecasts and improved profit margins due to increased cooperation revenue and cost reduction efforts [1] Group 2: Future Outlook - The company is expected to benefit from the rapid expansion of its already launched innovative products and the long-term value realization of its self-developed pipeline [1] - Recent potential significant business development (BD) transactions are anticipated to enhance revenue and support stock price growth [1]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index down 0.58% and the Shanghai Composite Index up 0.83% [1][3] - The US markets experienced declines, particularly in technology and consumer discretionary sectors, while defensive sectors like consumer staples and utilities saw gains [3] Hong Kong Stock Performance - The Hang Seng Financial Index fell by 1.08%, while the Hang Seng Real Estate Index dropped by 1.99% [2] - Despite the overall decline, selected sectors such as essential and discretionary consumer goods showed positive performance [3] Company Insights: China Biologic Products - China Biologic Products reported a 10.7% year-on-year revenue increase to 17.57 billion yuan in 1H25, with adjusted net profit rising 101.1% to 3.09 billion yuan [4][5] - The company’s innovative product revenue grew by 27.2%, accounting for 44.4% of total revenue, indicating strong market demand [5][6] - The firm is expected to maintain double-digit growth guidance for the year, driven by its robust pipeline and market expansion [6][7] Company Insights: Hansoh Pharmaceutical - Hansoh Pharmaceutical achieved a 14.3% year-on-year revenue increase to 7.43 billion yuan in 1H25, with net profit rising 33.4% to 3.14 billion yuan [8][9] - The company confirmed strong business development (BD) income, primarily from collaborations with MSD and GSK [9][10] - Hansoh's innovative drug sales are projected to exceed 10 billion yuan in 2025, supported by a strong pipeline and ongoing clinical trials [10][11] Company Insights: Xiaomi Group - Xiaomi reported a 31% year-on-year revenue increase and a 75% rise in net profit for Q2 2025, driven by strong performance in electric vehicles and IoT [12][13] - The company is adjusting its smartphone shipment guidance downward due to rising BOM costs, but remains optimistic about long-term growth strategies [12][13] - The new target price for Xiaomi is set at 62.96 HKD, reflecting a valuation based on segment performance [12] Company Insights: XPeng Motors - XPeng Motors reported a 14.3% gross margin in Q2 2025, exceeding expectations, while net losses narrowed compared to previous quarters [13][14] - The company is focusing on cost reduction and scale effects to improve profitability, with expectations for breakeven in Q3 2025 [14][15] - XPeng's sales forecast for 2025 has been adjusted to 450,000 units, with a target price of 28 USD [14][15] Company Insights: Palo Alto Networks - Palo Alto Networks reported a 15.8% year-on-year revenue increase to 2.5 billion USD in Q4 FY25, with non-GAAP net profit rising 28.9% [15] - The company is positioned as a key beneficiary in the generative AI era, with expectations for continued revenue and profit growth [15]

Group 1 - The core viewpoint of the report indicates that China Biopharmaceutical has experienced double-digit revenue growth in the first half of the year, driven by the expansion of innovative drugs and biosimilars [1] - The company benefited from investment income, leading to significant overall profit growth; however, the core pharmaceutical business's segment profit is slightly under pressure in the short term due to increased R&D investment [1] - Looking ahead, the firm remains optimistic about the rapid market penetration of its already launched innovative products, the long-term value realization of its self-developed pipeline, and the potential impact of recent significant BD transactions on revenue and stock price [1] Group 2 - The profit forecast for China Biopharmaceutical has been raised for the years 2025 to 2027, with adjusted net profit estimates of 5.1 billion, 4.4 billion, and 5.3 billion respectively [1] - The target price has been increased from 8 HKD to 9.1 HKD, maintaining a "buy" rating [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.40, representing a potential upside of 27.2% from the current price of HKD 7.39 [3][6]. Core Insights - The company reported a revenue growth of 10.7% year-on-year to RMB 17.57 billion in 1H25, with adjusted net profit increasing by 101.1% to RMB 3.09 billion. The revenue and adjusted net profit for 1H25 accounted for 54.6% and 79.6% of the full-year forecasts, respectively [1][6]. - The revenue from innovative products grew strongly by 27.2% year-on-year to RMB 7.80 billion, representing 44.4% of total revenue, indicating sustained rapid growth in innovative products [1][6]. - The management maintains a full-year guidance for double-digit organic growth based on the rapid growth of innovative products and stable expectations for generic drug business [1][6]. Financial Summary - For FY25E, the company is projected to achieve sales revenue of RMB 34.38 billion, reflecting a year-on-year growth of 19.1% [2][7]. - Adjusted net profit for FY25E is expected to reach RMB 6.27 billion, with a significant growth rate of 81.3% compared to the previous year [2][7]. - The adjusted earnings per share (EPS) for FY25E is forecasted at RMB 0.33, with an adjusted price-to-earnings (P/E) ratio of 20.5 times [2][7]. Pipeline and Market Potential - The company has a rich and differentiated pipeline, with several products showing potential for global top-tier status. The acquisition of Lixin Pharmaceutical has further strengthened its R&D capabilities [6][9]. - Key products such as TQB2868 (PD-1/TGF-β dual antibody) have shown impressive efficacy in clinical trials, with an overall response rate (ORR) of 63.9% in Phase II trials for pancreatic cancer, significantly higher than traditional chemotherapy [6][9]. - The company is expected to announce multiple important clinical data releases in 2H25, which could further enhance its market position [6][9].

Core Viewpoint - The recent surge in the A-share market, particularly in the technology, AI, innovative pharmaceuticals, and rare earth sectors, has been highlighted, with the Hang Seng Hong Kong Stock Connect Innovative Pharmaceutical Select Index (HSSCPB) leading the market with a year-to-date increase of 112.33% as of August 18, 2025 [1][4]. Group 1: Market Performance - The HSSCPB index has significantly outperformed other indices, with the Hang Seng Composite Index rising only 29.51% during the same period [4]. - The innovative pharmaceutical sector is recognized as a key driver of market sentiment, reflecting strong investor confidence in its future growth potential [4]. Group 2: Fund Launch and Investment Opportunities - The launch of the Hong Kong Stock Connect Innovative Pharmaceutical ETF (A Class 025220; C Class 025221) is set to provide investors with access to the innovative pharmaceutical sector, following the successful establishment of the ETF in June 2025 [1][2]. - The ETF is the first to track the HSSCPB index, which focuses on high-quality innovative pharmaceutical companies, offering a concentrated investment opportunity [7]. Group 3: Industry Trends and Future Outlook - The innovative pharmaceutical sector is characterized by its "essential + technology" attributes, making it a leading growth area within the pharmaceutical industry [3]. - The global pharmaceutical market is projected to reach $1.64 trillion in 2024, with innovative drugs accounting for $1.13 trillion, representing 68.9% of the market [4]. - China's innovative pharmaceutical companies are transitioning from contract manufacturing to global research and development, enhancing their competitiveness and global influence [5]. Group 4: Fund Management and Expertise - Huabao Fund, a pioneer in the ETF space, has a strong track record in the pharmaceutical and healthcare sectors, having launched several successful thematic funds [2][9]. - The firm has been recognized for its capabilities in index and ETF investment, with its equity ETF scale exceeding 100 billion yuan as of July 2025 [9].

Group 1: Hansoh Pharmaceutical (3692 HK) - The company is experiencing strong growth driven by innovative drugs and business development (BD) collaborations, with a 14% year-on-year revenue increase to 7.4 billion RMB in 1H25, including 1.7 billion RMB from collaborations [1] - Product sales, excluding collaboration income, grew by 13%, with innovative drug revenue increasing by 22% to 6.1 billion RMB, accounting for 82.7% of total revenue [1] - The company raised its full-year revenue guidance to a high double-digit percentage, maintaining sales targets for Amelot and overall innovative drugs at 6 billion and 10 billion RMB, respectively [1] Group 2: Amelot's Clinical Applications - Amelot's rapid market penetration is primarily driven by its first-line NSCLC indication, with additional approvals for adjuvant and III phase maintenance treatments in the first half of the year [2] - The sales peak forecast for Amelot has been raised to 9.7 billion RMB, with expectations of limited price reductions during the upcoming medical insurance negotiations [2] Group 3: China Biologic Products (1177 HK) - The company reported an 11% year-on-year revenue growth to 17.6 billion RMB in 1H25, driven by innovative product sales and investment income, with adjusted net profit increasing by 101% [3] - Revenue from innovative products grew by 27% to 7.8 billion RMB, contributing 44.4% to total revenue, an increase of 5.8 percentage points year-on-year [3] - The company maintains its guidance for full-year revenue to achieve double-digit growth [3] Group 4: Long-term Growth Drivers - The company is developing a comprehensive pipeline with differentiated self-research products, expecting significant BD opportunities from 2H25 to 2026, focusing on various innovative drug candidates [4][6] - The acquisition of Lixin Pharmaceutical has further expanded the company's oncology pipeline, with management projecting over 35 innovative products by 2027, contributing 60% to revenue [6] Group 5: Tongcheng Travel (780 HK) - The company’s Q2 performance met expectations, with a projected 15% year-on-year revenue growth in core OTA business for Q3, driven by a 10-15% increase in accommodation nights [7] - The full-year core OTA business is expected to grow by 16%, with operating profit margins improving by approximately 2 percentage points due to strategic shifts towards enhancing user ARPU and profitability in new business areas [7]

Group 1: Company Insights - The report initiates coverage on Mai Fushi (2556.HK) with a "Buy" rating, projecting a target market value of 18.65 billion RMB, indicating a 50% upside potential from current levels [2] - Mai Fushi's revenue is expected to grow significantly, with forecasts of 2.31 billion, 2.97 billion, and 3.82 billion RMB for 2025-2027, reflecting year-on-year growth rates of 48%, 29%, and 29% respectively [13] - The company has a strong execution capability, with an average revenue per employee of 997,000 RMB in 2024, indicating effective operational management [13] Group 2: Industry Trends - The report discusses the ongoing trend of "residential deposit migration," which is expected to accelerate as the equity market's fundamentals improve, with A-shares currently positioned favorably [12] - The report highlights that the equity market is likely to become the next destination for residential asset allocation, as the previous "stock-property seesaw" effect is no longer a constraint [15] - The report notes that by Q4 2025, the real risk-free interest rate for residents is expected to decline significantly, which will further drive the migration of deposits into the equity market [15] Group 3: Competitive Landscape - The competitive landscape for Mai Fushi is characterized by a focus on mid-to-large enterprises, which enhances customer retention and bargaining power [13] - The report emphasizes the differentiation of Mai Fushi's products compared to competitors like Weimeng and Youzan, particularly in terms of comprehensive service offerings and a full-link marketing approach [13] - The report indicates that the AI commercialization acceleration is a key catalyst for growth, with a notable increase in KA customer numbers and order sizes [13] Group 4: Market Performance - The report notes that the A-share market has shown signs of recovery, with a significant increase in the Shanghai Composite Index by 5.46% over the past month [1] - The report identifies sectors such as black home appliances and animal health as having strong recent performance, with respective increases of 12.36% and 47.87% over the past month [4] - Conversely, sectors like medical services and aviation equipment have underperformed, with declines of 10.77% and 21.91% over the same period [4]

Group 1 - The A-share takeover market has seen significant activity this year, with 17 companies involved in takeover bids, surpassing last year's total of 11 [1] - The takeover bids include both voluntary and involuntary offers, as well as full and partial bids, with participants including major shareholders and listed companies [1] - Following the announcement of takeover bids, companies such as Shenkai Co., Haobor, and ST Xinchao experienced substantial stock price increases [1] Group 2 - Shenkai Co. announced a takeover bid by Shenzhen Huili Hongsheng Industrial Holdings at a price of 16.13 yuan per share, with a bid period from July 29 to August 27 [1] - The acquisition of 41.89% of Shenkai Co.'s shares triggered a full takeover obligation, requiring offers to all shareholders except the controlling shareholder and the second-largest shareholder [1] - The takeover market this year has seen several instances of one listed company acquiring another, such as Hainan Airport's bid for Meilan Airport and China Biopharmaceutical's bid for Haobor [2] Group 3 - The primary purposes of the takeover bids this year include horizontal integration within industries, consolidation of control by major shareholders, and obtaining controlling stakes in listed companies [2] - The core principle of arbitrage in takeover bids is the price difference between the secondary market and the offer price, with higher premiums and larger bid proportions leading to more significant stock price boosts [2]

Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Biopharmaceutical (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% stake in Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans to issue shares at a discount of approximately 9.9%, raising HKD 468 million [1] Financial Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, up 133.51% year-on-year [1] - Pop Mart (09992) announced a mid-term profit of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, up 37.33% year-on-year [1] - China Resources Beer (00291) announced a mid-term profit of HKD 5.789 billion, an increase of 23.04% year-on-year [1] - Kunlun Energy (00135) reported a mid-term profit of HKD 3.161 billion, down 4.36% year-on-year, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit of approximately HKD 2.339 billion, up 56% year-on-year [1] - Sunny Optical Technology (02382) announced a mid-term profit of HKD 1.646 billion, an increase of 52.56% year-on-year [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, up 28% year-on-year [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit of HKD 498 million, up 24.6% year-on-year, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) achieved record levels in core business and financial metrics for Q2, with a net loss of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit of HKD 121 million, up 76% year-on-year [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term profit of approximately HKD 305 million, up 154.81% year-on-year [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit of HKD 3.519 billion, down 14.4% year-on-year [1] - Yancoal Australia (03668) reported a mid-term profit of AUD 16.3 million, down 61.19% year-on-year [1] - SF Holding (06936) reported total revenue of HKD 24.847 billion for July in logistics, supply chain, and international business, up 9.95% year-on-year [1] - Chow Sang Sang (00116) expects a mid-term profit from continuing operations of approximately HKD 900 million to HKD 920 million [1]

Group 1 - Xiaomi Group-W (01810.HK) reported a record revenue of RMB 116 billion and a net profit of RMB 10.8 billion for Q2 2025, marking a year-on-year increase of 30.5% and 75.4% respectively [1] - The "Mobile × AIoT" segment generated RMB 94.7 billion in revenue, up 14.8% year-on-year, while the "Smart Electric Vehicles and AI Innovation" segment reached RMB 21.3 billion, both achieving historical highs [1] - The total smartphone shipments for Q2 2025 were 42.4 million units, reflecting a 0.6% year-on-year growth, maintaining a global market share of 14.7% and ranking among the top three for 20 consecutive quarters [2] Group 2 - Xiaomi's active user base reached a record high of 731.2 million globally by June 2025, representing an 8.2% year-on-year increase [2] - The number of connected IoT devices on Xiaomi's AIoT platform grew to 989.1 million, a 20.3% increase year-on-year [2] - Research and development expenditure for Q2 2025 was RMB 7.8 billion, up 41.2% year-on-year, with the number of R&D personnel reaching a historical high of 22,641 [2] Group 3 - Xiaomi's retail presence expanded significantly, with over 1,700 new Xiaomi Home stores opened in mainland China, bringing the total to over 17,000, while international retail stores reached approximately 200 [2]